Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy
Author(s) -
Imalka Munaweera,
Bhuvaneswari Koneru,
Yi Shi,
Anthony J. Di Pasqua,
Kenneth J. Balkus
Publication year - 2014
Publication title -
apl materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.571
H-Index - 60
ISSN - 2166-532X
DOI - 10.1063/1.4899118
Subject(s) - mesoporous silica , materials science , nanocarriers , zeta potential , nanoparticle , mesoporous material , drug delivery , platinum nanoparticles , nanomaterials , platinum , fourier transform infrared spectroscopy , nanotechnology , chemical engineering , kinetics , organic chemistry , chemistry , catalysis , physics , quantum mechanics , engineering
Over the last decade, the development and application of nanotechnology in cancer detection, diagnosis, and therapy have been widely reported. Engineering of vehicles for the simultaneous delivery of chemo- and radiotherapeutics increases the effectiveness of the therapy and reduces the dosage of each individual drug required to produce an observable therapeutic response. We here developed a novel chemoradiotherapeutic 1,2-dioleoyl-sn-glycero-3-phosphocholine lipid coated/uncoated platinum drug loaded, holmium-containing, wrinkled mesoporous silica nanoparticle. The materials were characterized with TEM, FTIR, 1H NMR, energy dispersive x-ray, inductively coupled plasma-mass spectrometry, and zeta potential measurements. In vitro platinum drug release from both lipid coated and uncoated chemoradiotherapeutic wrinkled mesoporous silica are reported. Various kinetic models were used to analyze the release kinetics. The radioactivity of the chemoradiotherapeutic nanocarriers was measured after neutron-activation
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom